Physiomics Announces License Agreement with Eli Lilly
07-Apr-2009
- United Kingdom
‘We are delighted with the continued interest shown by Lilly in Physiomics’ technology. We hope that the capability for Lilly scientists to directly use Physiomics’ models will strengthen the quality of the interactions within our ongoing research collaborations. This is also an important commercial and technical milestone for Physiomics as this is the first time that we have out-licensed our technology.’
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
Chemieschule Dr. Elhardt GmbH - München, Germany
Go to page
Sufentanil
Go to page
First cancer immunotherapy for dogs developed
Go to page
AuWeKo GmbH - Neu-Isenburg, Germany
Go to page
Lpath Inc. - San Diego, USA
Go to page
Chemgineering Holding AG - Münchenstein, Switzerland
Go to page
Polyscytalum_pustulans
Go to page